Skip to main navigation Skip to search Skip to main content

Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial

  • Lorinda Chung
  • , Cathie Spino
  • , Richard McLain
  • , Sindhu R. Johnson
  • , Christopher P. Denton
  • , Jerry A. Molitor
  • , Virginia D. Steen
  • , Robert Lafyatis
  • , Robert W. Simms
  • , Suzanne Kafaja
  • , Tracy M. Frech
  • , Vivien Hsu
  • , Robyn T. Domsic
  • , Janet E. Pope
  • , Jessica K. Gordon
  • , Maureen D. Mayes
  • , Nora Sandorfi
  • , Faye N. Hant
  • , Elana J. Bernstein
  • , Soumya Chatterjee
    • Flavia V. Castelino, Ali Ajam, Yannick Allanore, Marco Matucci-Cerinic, Michael L. Whitfield, Oliver Distler, Ora Singer, Amber Young, Vivek Nagaraja, David A. Fox, Daniel E. Furst, Dinesh Khanna

Research output: Contribution to journal › Article › peer-review

45   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science